Dirk Kersten Sells 79,411 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Dirk Kersten sold 79,411 shares of the business’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $36.45, for a total value of $2,894,530.95. Following the transaction, the director now owns 234,127 shares in the company, valued at $8,533,929.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Dirk Kersten also recently made the following trade(s):

• On Monday, September 23rd, Dirk Kersten sold 40,831 shares of Dyne Therapeutics stock. The stock was sold at an average price of $35.32, for a total value of $1,442,150.92.

Dyne Therapeutics Stock Performance

Shares of NASDAQ DYN traded down $1.23 during mid-day trading on Tuesday, hitting $33.40. 1,936,244 shares of the stock were exchanged, compared to its average volume of 1,608,944. Dyne Therapeutics, Inc. has a twelve month low of $6.40 and a twelve month high of $47.45. The stock’s fifty day simple moving average is $40.89 and its two-hundred day simple moving average is $33.71. The company has a market cap of $2.92 billion, a P/E ratio of -8.72 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.02. As a group, equities research analysts predict that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in DYN. Nisa Investment Advisors LLC grew its holdings in Dyne Therapeutics by 904.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after acquiring an additional 669 shares during the last quarter. Amalgamated Bank lifted its position in shares of Dyne Therapeutics by 39.9% during the second quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock worth $99,000 after purchasing an additional 796 shares in the last quarter. Public Employees Retirement Association of Colorado bought a new stake in shares of Dyne Therapeutics during the second quarter valued at approximately $203,000. Ameritas Investment Partners Inc. increased its holdings in shares of Dyne Therapeutics by 28.0% in the first quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock valued at $167,000 after purchasing an additional 1,291 shares in the last quarter. Finally, Farallon Capital Management LLC bought a new position in Dyne Therapeutics in the 2nd quarter worth approximately $212,000. 96.68% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

DYN has been the subject of a number of recent research reports. Stifel Nicolaus upped their target price on Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Morgan Stanley increased their price objective on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Piper Sandler reiterated an “overweight” rating and set a $53.00 target price on shares of Dyne Therapeutics in a research report on Monday. HC Wainwright reissued a “buy” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research report on Wednesday, September 4th. Finally, StockNews.com downgraded Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. One research analyst has rated the stock with a sell rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $51.40.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.